HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan

HBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan

San Diego, CA, USA – December 22, 2015HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

Read more

HUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP Awards

Supports Prestigious Award Recognizing Excellence in Pharmaceutical Development

San Diego, CA, USA – December 3, 2015HUYA Bioscience International (HUYA) was a proud sponsor of the ‘Best New Drug’ category at the 11th Annual SCRIP Awards. Dr. Mireille Gillings was a finalist for ‘Executive of the Year’ and HUYA was a finalist for ‘Best Company in an Emerging Market’. These prestigious awards recognize excellence in the biopharmaceutical industry. HUYA CEO and Executive Chairman, Dr. Mireille Gillings, presented HUYA Bioscience’s Best New Drug Award to Novartis which was recognized for the launch of its new product Cosentyx (secukinumab), a therapy for psoriasis. The award was presented at a ceremony at the Grosvenor House Hotel in London, attended by over 300 industry leaders.

Read more

HUYA Bioscience International Expands into South Korea

Seoul Office Will Head Operations to Develop Korean Biopharmaceutical Innovation

Seoul, Korea – December 2, 2015HUYA Bioscience International (HUYA), the global leader in accelerating drug discovery and development of biopharma innovation originating in China, recently opened its first Corporate office in Korea. This continues to build on HUYA’s overall strategy to be the partner-of-choice for innovative pharmaceutical companies in emerging centers of excellence worldwide.

Read more